Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value

被引：38

作者：

Serritella, Anthony V. ^{[1
]}

Strohbehn, Garth W. ^{[1
,2
]}

Goldstein, Daniel A. ^{[2
,3
,4
,5
]}

Lichter, Allen S. ^{[2
]}

Ratain, Mark J. ^{[1
,2
]}

机构：

[1] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA

[2] Value Canc Care Consortium, Ann Arbor, MI USA

[3] Tel Aviv Univ, Tel Aviv, Israel

[4] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel

[5] Univ North Carolina, Gillings Sch Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC 27515 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 108卷 / 03期

关键词：

GRAPEFRUIT JUICE; FOOD; ONCOLOGY; CHEMOTHERAPY; ABIRATERONE; THERAPIES; COST; MEAL;

D O I：

10.1002/cpt.1853

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer care's sustainability is challenged by drug expenditures. In the absence of systemic change, innovation is needed to curtail drug costs. Interventional pharmacoeconomics (IVPE) utilizes clinical research to identify safe, efficacious, cost-conscious dosing regimens to extract maximum value from expensive therapies. Strategies include de-escalation of dosage, treatment duration and administration frequency, and substitution with therapeutic alternatives. In this review, we discuss how IVPE strategies have been successfully used and could be implemented going forward.

引用

页码：487 / 493

页数：7

共 56 条

[1]

ALBERTY E, FIGHT HIGH DRUG PRIC

[2]

[Anonymous], Prostate Cancer

[3] Overspending driven by oversized single dose vials of cancer drugs [J].

Bach, Peter B. ;

Conti, Rena M. ;

Muller, Raymond J. ;

Schnorr, Geoffrey C. ;

Saltz, Leonard B. .

BMJ-BRITISH MEDICAL JOURNAL, 2016, 352

[4] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis [J].

Baxi, Shrujal ;

Yang, Annie ;

Gennarelli, Renee L. ;

Khan, Niloufer ;

Wang, Ziwei ;

Boyce, Lindsay ;

Korenstein, Deborah .

BMJ-BRITISH MEDICAL JOURNAL, 2018, 360

[5]

BENET L, 1995, METHOD INCREASING BI

[6] Effects of Food on the Pharmacokinetics of Nilotinib in Chronic Myeloid Leukemia: Enabling Significant Dose Reduction and Relief of Treatment Burden: The NIFOStudy [J].

Boons, Christel C. ;

den Hartog, Yvonne ;

Janssen, Jeroen J. ;

Zandvliet, Anthe S. ;

Vos, Rene ;

Swart, Eleonora L. ;

Hendrikse, N. Harry ;

Hugtenburg, Jacqueline G. .

BLOOD, 2018, 132

[7]

Bressler R, 2006, GERIATRICS, V61, P12

[8] Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis [J].

Campiotti, Leonardo ;

Suter, Matteo Basilio ;

Guasti, Luigina ;

Piazza, Rocco ;

Gambacorti-Passerini, Carlo ;

Grandi, Anna Maria ;

Squizzato, Alessandro .

EUROPEAN JOURNAL OF CANCER, 2017, 77 :48-56

[9]

CAVALLO J, TACKLING HIGH COST C

[10] A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia [J].

Chen, Lisa S. ;

Bose, Prithviraj ;

Cruz, Nichole D. ;

Jiang, Yongying ;

Wu, Qi ;

Thompson, Philip A. ;

Feng, Shuju ;

Kroll, Michael H. ;

Qiao, Wei ;

Huang, Xuelin ;

Jain, Nitin ;

Wierda, William G. ;

Keating, Michael J. ;

Gandhi, Varsha .

BLOOD, 2018, 132 (21) :2249-2259

← 1 2 3 4 5 6 →